TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07287995: A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 428 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07287995 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07287995 Rescue Dossier →